AEZS: Headlines for AEterna Zentaris, Inc. - Yahoo! Canada Finance

Wed, Feb 3, 2010
•	AEterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of PRNewswire (Wed, Feb 3)
•	Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of CNW Group (Wed, Feb 3)
•	Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer PR Newswire (Wed, Feb 3)
Fri, Jan 29, 2010
•	Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglo CNW Group (Fri, Jan 29)
•	AEterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macrogl PRNewswire (Fri, Jan 29)
•	Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia PR Newswire (Fri, Jan 29)
•	Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglo PRNewswire (Fri, Jan 29)
•	Biotech Stock Mailbag: Keryx Biopharmaceuticals at TheStreet.com (Fri, Jan 29)
Wed, Jan 27, 2010
•	Keryx Biopharmaceuticals, Inc. to Conduct Conference Call to Discuss KRX-0401 (Perifosine) Clinical Development Program in Colorectal Cancer PRNewswire (Wed, Jan 27)
•	UPDATE - Spectrum to end development of enlarged-prostate drug at Reuters (Wed, Jan 27)
Tue, Jan 26, 2010
•	Liberty Analytics Co. Initiates Independent Research Coverage on AEterna Zentaris Inc. GlobeNewswire (Tue, Jan 26)
Mon, Jan 25, 2010
•	Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Cont CNW Group (Mon, Jan 25)
•	AEterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Con PRNewswire (Mon, Jan 25)
•	Keryx Reports Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of KR PRNewswire (Mon, Jan 25)
Fri, Jan 22, 2010
•	AEterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price PRNewswire (Fri, Jan 22)
•	Æterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price CNW Group (Fri, Jan 22)
Thu, Jan 21, 2010
•	AEterna Zentaris Partner, Keryx Biopharmaceuticals, to Present Poster Highlighting Clinical Activity of Perifosine (KRX-0401) at the ASCO 2010 Gastroi PRNewswire (Thu, Jan 21)
•	Æterna Zentaris Partner, Keryx Biopharmaceuticals, to Present Poster Highlighting Clinical Activity of Perifosine (KRX-0401) at the ASCO 2010 Gastroin CNW Group (Thu, Jan 21)
•	Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the ASCO 2010 Gastrointestinal Cance PRNewswire (Thu, Jan 21)
Mon, Dec 21, 2009
•	The Complete List of Canadian Stocks Traded on the Nasdaq at Seeking Alpha (Mon, Dec 21)
Sun, Dec 20, 2009
•	This Week's Failed Trials, Missed Targets in Biotech at Seeking Alpha (Sun, Dec 20)
Fri, Dec 18, 2009
•	Æterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Beni CNW Group (Fri, Dec 18)
Older Headlines
View headlines from:

Add to Portfolio

Email to a Friend

•